| | Author | Country | | Age
(median) | Tumor grade
(I.II/III.IV) | Tumor size (<=cm/>, unclear) | Sampling
site | Tumor
type | Histological
type | Histological differentiation
(G1/G2, G3, and unknown) | Method | Attitude | Follow-up time
(median) | Survival outcome
(OS, DFS) | Cutoff | MicroRNA type |
| |
Buffa FM, 2011 | UK | 219 | 55 | NR | 2.3 (median) | Tissue | Breast cancer | Ductal, lobular, mixed, and others | 129, 65, and 25 | qRT-PCR | Neg | 10 y | DFRS, RFS | Median | miR-128a, -342, -27b, -150 | |
Foekens JA, 2008 | The Netherlands | 298 | 52 | NR | 2 cm, 141/157 | Tissue | Breast cancer | ER+/LNN, triple-negative | 44, 161, and 93 | qRT-PCR | Pos | 99 m | MFS | Median | miR-7, -128a, and -516-3p | |
Gee et al., 2010 [19] | UK | 46 | 63 |
8, 38 | NR | Tissue | Head and neck cancers | HNSCC | 27, 19 | qRT-PCR | Pos | 41 m | OS, RFS | Median | miR-21, -10b | |
Greithe T1, 2009 | Germany | 56 | 61.7 | NR | NR | Tissue | Pancreatic cancer | PDAC | NR | qRT-PCR | Pos | 15.99 m | DSS | Median | miR-155, -203, -216, -217, and -222 | |
Greithe T2, 2011 | Germany | 78 | 57 | 44, 34 | NR | Tissue | Soft-tissue sarcoma | STS, LS, MFH, FS, RMS, LMS, NS, and Syn | 48, 30 | qRT-PCR | Pos | 66 m | DSS | Quartiles | | |
Rothe F, 2011 | USA | 73 | NR | NR | 2 cm, 43/29/1 | Tissue | Breast cancer | ER-positive, ER-negative | 35, 22, and 16 | qRT-PCR | Pos | 9.23 y | RFS | Median | miR-148a | | | | 89 | NR | NR | 2 cm, 34/55 | Tissue | Breast cancer | ER-positive | 64, 17, and 8 | qRT-PCR | Pos | 7.12 y | RFS | Median | miR-149a | |
Toyama T, 2012 | Japan | 161 | NR | NR | 2 cm, 42/117/2 | Tissue
| Breast cancer | TNBC, ER-positive, HER2-negative | 86, 53, and 22 | qRT-PCR | Pos | 5.4 y | DFS, OS | Median | | |
Volinia S, 2012 | Italy, Columbia | 107 | NR | NR | NR | Tissue | Breast cancer | DCIS, IDC, metaplastic, atypical, medullary, apocrine, adenoid, normal | NR | qRT-PCR | Pos | NR | MFS, OS | Median | miR-127-3p, -185, -143, -let-7b, -21, -221, -652, -106b, -197, and -let-7i | |
Wotschofsky Z, 2012 | Germany | 89 | 65 | 55, 34 | 5 (median) | Tissue | Renal cell carcinoma | ccRCC nonmetastatic | 81, 8 | qRT-PCR | Neg | 33.8 m | RFS | Median | miR-122, -141, -155, -184, -200c, -224, and -514 | | | | 22 | 62 | 3, 19 | 9 (median) | Tissue | Renal cell carcinoma | ccRCC metastatic | 8, 14 | qRT-PCR | Neg | 9.4 m | RFS | Median | miR-122, -141, -155, -184, -200c, -224, and -515 |
|
|
